{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012215","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.424103+00:00","generated_at":"2026-06-24T22:36:21.693104+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sutro Biopharma enters $90M upfront license deal with Astellas for ADCs up to 3 targets","bullets":["Astellas pays $90M upfront; Sutro eligible for up to $422.5M in milestones plus tiered royalties (low double-digit to mid-teen %).","Sutro can elect US cost/profit sharing on any product candidate, replacing royalties in the US.","Deal covers up to 3 biological targets selected by Astellas; Sutro handles preclinical development.","Termination includes Astellas' convenience termination on 30 days' notice and mutual termination for material breach."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012215","json":"https://secwatch.observer/filing/0000950170-22-012215.json","markdown":"https://secwatch.observer/filing/0000950170-22-012215.md","text":"https://secwatch.observer/filing/0000950170-22-012215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022012215/0000950170-22-012215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022012215/stro-20220627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:36:21.693104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}